Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease

Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease

OSAKA, Japan, June 3, 2018 /PRNewswire/ — Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW) 2018 meeting Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today

Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings

May 17, 2018 – Data Being Presented Underscore Commitment to Improving Patient Outcomes and Care – Six Takeda Oncology-Sponsored Abstracts Accepted for Presentation at ASCO 2018 and Eight Abstracts Accepted for Presentation at EHA 2018   Cambridge, Mass. and Osaka,

Execution of Bridge Loan Agreement for Shire plc Acquisition

Osaka, Japan, May 8, 2018 — Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka, the “Company or “Takeda”) announces that it has entered into a “364-Day Bridge Credit Agreement” (the “Bridge Credit Agreement”) for an aggregate principal amount of up to 30.85

Proposed Acquisition of Shire plc by Takeda

May 8, 2018 Osaka, Japan – Creates a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan – – Better positions Takeda to deliver highly-innovative medicines and transformative care globally – – Accelerates strategic transformation toward Vision 2025 – Transaction Highlights Brings together

TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)

May 2, 2018 First antidepressant with U.S. labelling approved with Digit Symbol Substitution Test (DSST) data recognized as a clinically meaningful measure in acute MDD Osaka, Japan and Deerfield, Ill. (May 2, 2018) – Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502)

Takeda Announces Voluntary and Conditional Public Takeover Bid for Outstanding Shares, Warrants and American Depositary Shares of TiGenix NV to Commence April 30, 2018

April 25, 2018 Osaka, Japan Prospectus and response memorandum approved by the FSMA on April 24, 2018 and to be published on April 27, 2018 Initial acceptance period will commence on April 30, 2018 and expire on May 31, 2018, subject